- |||||||||| ATLCAR.CD30.CCR4 cells / UNC Lineberger Comprehensive Cancer Center, TT11 / Tessa Therap, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Research Institute
Enrollment open, IO biomarker: ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells (clinicaltrials.gov) - Jun 21, 2024
P1/2, N=31, Recruiting,
Not yet recruiting --> Recruiting
- |||||||||| ATLCAR.CD30.CCR4 cells / UNC Lineberger Comprehensive Cancer Center, TT11 / Tessa Therap, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Research Institute
New P1/2 trial, IO biomarker: ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells (clinicaltrials.gov) - Oct 19, 2023
P1/2, N=31, Not yet recruiting,
- |||||||||| ATLCAR.CD30.CCR4 cells / UNC Lineberger Comprehensive Cancer Center, Actemra IV (tocilizumab) / Roche, JW Pharma
CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma (GWCC - A411-A412, Level 4) - Nov 5, 2021 - Abstract #ASH2021ASH_2237;
P1
All patients receive lymphodepletion with 3 days of bendamustine 70 mg/m 2 and fludarabine 30 mg/m 2...All patients had received prior brentuximab vedotin...Two patients had grade 2 cytokine release syndrome (CRS) which resolved with tocilizumab, and 1 had self-limiting grade 1 CRS...Interestingly, responses are already seen at the lowest dose level, suggesting that early tumor homing driven by CCR4 may allow more fitted cells to better exploit their antitumor potential. Our data serve as a proof of concept for future modifications of CAR-T cells to improve their localization to disease sites.
- |||||||||| ATLCAR.CD30.CCR4 cells / UNC Lineberger Comprehensive Cancer Center, TT11 / Tessa Therap, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Research Institute
Enrollment change, Trial completion date, Trial primary completion date, CAR T-Cell Therapy: LCCC 1606-ATL: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (clinicaltrials.gov) - Jan 9, 2020
P1, N=59, Recruiting,
Our data serve as a proof of concept for future modifications of CAR-T cells to improve their localization to disease sites. N=36 --> 59 | Trial completion date: May 2036 --> Sep 2041 | Trial primary completion date: May 2021 --> Sep 2026
- |||||||||| ATLCAR.CD30.CCR4 cells / UNC Lineberger Comprehensive Cancer Center, TT11 / Tessa Therap, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Research Institute
Enrollment open, CAR T-Cell Therapy: LCCC 1606-ATL: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (clinicaltrials.gov) - Sep 28, 2018
P1, N=36, Recruiting,
N=36 --> 59 | Trial completion date: May 2036 --> Sep 2041 | Trial primary completion date: May 2021 --> Sep 2026 Not yet recruiting --> Recruiting
|
